Rafferty Asset Management
SLS icon

Rafferty Asset Management’s SELLAS Life Sciences SLS Stock Holding History

Rafferty Asset Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.54M Sell
239,892
-9,536
-4% -$65.8K 0.01% 481
2026
Q1 		$1.06M Buy
+249,428
New +$1.12M ﹤0.01% 752

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Rafferty Asset Management's SLS Position: Q2 2026 in Review

Rafferty Asset Management reduced its SELLAS Life Sciences (SLS) stake by 3.8% in Q2 2026, selling an estimated $65.8K and leaving 239,892 shares worth $3.54M. The position accounts for 0.01% of the portfolio, ranked #481.

Rafferty Asset Management first reported a position in SLS in Q1 2026 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Rafferty Asset Management held 239,892 shares of SELLAS Life Sciences worth $3.54M as of Q2 2026.
  • Rafferty Asset Management sold 9,536 SELLAS Life Sciences shares in Q2 2026, an estimated $65.8K.
  • SELLAS Life Sciences made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #481 holding.
  • Rafferty Asset Management first reported a position in SELLAS Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.